Search Results for: GPG: Versione 5.0 (25 Novembre 2019)

Il 50% dei pazienti non lo conosce. Medici, vaccini per fragili

Il Virus Respiratorio Sinciziale (RSV) rappresenta un grave problema di salute pubblica globale. In Italia, ogni anno, tra gli over 60 si stimano 26mila ospedalizzazioni e 1.800 decessi in ambito ospedaliero. Come emerge dalla survey dell’Associazione Pazienti con BPCO, il 50% dei pazienti non conosce l’infezione

In a large observational study, risk for cardiovascular disease was 25% lower among vaccinated people.

Dynamic autoregulation monitoring based on LLA was associated with outcomes in paediatric TBI with higher LLA values observed in individuals experiencing unfavourable outcomes. Our findings indicate that the current fixed CPP threshold of 40–50 mmHg may be too low–highlighting the need for further investigation into autoregulation-guided CPP targets. Whether personalised management based on autoregulatory-informed thresholds offers advantages over guideline-based targets remains to be determined and should be investigated in future prospective interventional studies.

Per nati 1990 rischio doppio a colon. Pesa cibo, alcol,poco moto

Per nati 1990 rischio doppio di cancro colon

Stroke, Ahead of Print. BACKGROUND:Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic.METHODS:This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale.RESULTS:The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3];P

Solo 25% documenti disponibili ovunque, pochi sì dei cittadini

Colpisce il 20-50% degli operati. Proposta giornata nazionale

The RCOG World Congress 2025 took place at the London ExCeL Centre on June 23–25, hosting over 2500 delegates from around 100 countries and delivering over 70 sessions with more than 220 global speakers. Under the theme of “Equity in care, innovation in action”, the programme covered an impressive range of topics, relevant to both UK and global audiences, including women’s health (eg, menopause, sexual health, inequalities in access to care, cancer, endometriosis, vulval disease, human papillomavirus (HPV) vaccination, and imaging in gynaecology), fertility and reproduction (eg, developments in assisted reproduction, abortion, and contraception), and pregnancy and post-partum care (eg, preterm birth, obstetric fistula, foetal imaging, and postpartum complications), as well as the emerging role of artificial intelligence (AI) and digital health across these topics.

Screen use, the time spent engaging with electronic devices such as mobile phones and tablets, can become addictive when individuals experience difficulty stopping despite attempts to do so, as well as symptoms of withdrawal, tolerance, conflict, and relapse (BoxBox). Adolescence is a vulnerable period for addictive behaviors, and recent findings suggest that young adolescents are particularly susceptible to screen addiction. Notably, in the US, 48% of young adolescents report losing track of how much they are using their phone, 25% use social media to forget about their problems, and 25% admit to spending a considerable amount of time thinking about social media apps. Furthermore, 17% have tried to reduce their social media use but cannot, and 11% acknowledge that their screen use has negatively affected their schoolwork. These statistics highlight the need to study screen addiction and its specific health effects, as understanding these behaviors is crucial for addressing the risks they pose to adolescents’ well-being.

This study examines the impact of the MAT Act on trends in pharmacist-prescribed buprenorphine from US retail pharmacies from 2019 to 2024.

Nei pazienti con psoriasi a placche da moderata a grave, il trattamento con bimekizumab ha dimostrato alti tassi di risposta clinica e di miglioramento della qualità di vita correlata alla salute nell’arco di 5 anni, come evidenziato dai dati dello studio BE BRIGHT presentati al congresso della Society of Dermatology Physician Associates (SDPA) tenutosi a Washington, DC, dal 25 al 29 giugno.

La Food and Drug Administration (Fda) ha rifiutato l’approvazione di deramiocel (CAP 1002), la terapia cellulare di Capricor Therapeutics destinata alla cardiomiopatia associata alla distrofia muscolare di Duchenne (DMD). Con un calo del valore azionario che ha superato il 50% in pre-apertura, la reazione dell’azienda è stata di sorpresa. 

Circulation, Ahead of Print. BACKGROUND:Abdominal aortic aneurysms (AAA) present with high morbidity and mortality when they occasionally rupture. No medical therapy has successfully been proven to reduce AAA growth, though both metformin and statins have been identified as potential treatments in multiple meta-analysis. This study aimed to investigate a potential relationship between statin use and AAA growth rates and risk of undergoing repair, rupture, or death.METHODS:The study population included all men with screening-detected AAAs (30–55 mm) from the 2 large, population-based, randomized screening trials; the Viborg Vascular Screening trial (inclusion, 2008–2011) and the Danish Cardiovascular Screening trial (inclusion, 2014–2018). The clinical database was supplemented with data from the nationwide Danish Healthcare Registries, including prescription and outcome data. Statin exposure was quantified by defined daily doses (DDD). The primary outcome was AAA growth rate, whereas secondary outcomes included the need for repair and a composite of repair, rupture, and all-cause death. Growth rates were calculated using linear regression. To evaluate the risk of repair, patients were followed from inclusion until surgery, rupture, death, 5-year follow-up, or December 31, 2021.RESULTS:A total of 998 aneurysmal men (median age, 69.5 [interquartile range (IQR), 67–72] years; median AAA diameter, 35.4 [IQR, 32–41.2] mm) were included. Statin use was significantly associated with reduced AAA growth rate; an increase of 1 DDD statin per day was associated with an adjusted change in growth rate of −0.22 mm/year [95% CI, −0.39 to −0.06];P=0.009). The 5-year adjusted hazard ratio for undergoing repair per doubling of statin dose presented a significantly reduced adjusted hazard ratio (HR) of 0.82 ([95% CI, 0.70–0.97];P=0.023), which was significant after 2.5 years. Statin use was associated with a significantly lower risk of the composite outcome (surgery, rupture, and death) in a dose-dependent manner, with an adjusted HR of 0.83 ([95% CI, 0.73–0.94];P=0.003) per doubling of statin dose. Findings were robust in a variety of sensitivity analyses.CONCLUSIONS:High-dose statin use was associated with decreased AAA growth rates and lowered risk of undergoing repair, rupture, and death. This nonrandomized study suggests that patients with AAA could benefit from high-dose statin use, beyond only targeting associated risk factors.